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Poster Session I 95minimally invasive assays to be used following mass radiation expo-
sure from biological information stored in the human body. Study
Aim: The goals of this study were to: 1.) identify potential bio-
dosimetry genes from cancer patients following total body irradia-
tion (TBI); 2.) use gene expression analysis in an in vitro system to
develop mathematical models capable of determining radiation
dose received by exposed individuals. Methods/Results: Blood
samples were collected at 5 and 23 hours post-TBI from three pa-
tients with acute lymphocytic leukemia treated over three days
with 2 daily 2 Gy fractions (12 Gy total). Low density array analysis
revealed 15 genes with increased expression post-irradiation. In vi-
tro studies utilized immortalized B lymphocytes irradiated at 0.1,
0.5, 1, and 2 Gy and harvested 3, 5, 9, 12, and 23 hours post-irradi-
ation. Of the 15 genes identified in patients, 10 demonstrated sim-
ilar expression profiles in B lymphocytes. Leukemia Inhibitory
Factor (LIF) and Serine Protease Inhibitor E1 (SERPINE1) dis-
played linear dose-dependent increases in expression at every
time-point as determined by linear regression analyses (r2-val-
ues$0.76, p\ 0.0001). LIF and SERPINE1 followed a time-de-
pendent cubic model of expression to be validated in expanded
time-point studies. Conclusion: The determination of LIF and
SERPINE1 expression may be useful in determining dose of radia-
tion exposure and may subsequently facilitate stratification of indi-
viduals requiring medical intervention.SUPPORTIVE CARE257
DECREASE OF HHV6 DNAemia FOLLOWING ALLOGENEIC HEMATOPOI-
ETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH CHROMOSO-
MALLY INTEGRATED HHV6
Hubacek, P.1, Hrdlickova, A.2, Muzikova, K.1, Hyncicova, K.2,
Pohlreich, D.3, Cetkovsky, P.3, Sedlacek, P.1. 1Teaching Hospital Motol,
2ndMedical School, Charles University, Prague, Czech Republic; 2Teach-
ing Hospital Motol, 2nd Medical School, Charles University, Prague,
Czech Republic; 3 Institute of Hematology and Blood Transfusion, Prague,
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Immunocompromised patients could suffer from clinical conse-
quences of infection with the human herpesvirus 6 (HHV6). Using
PCRmethods, we are now able to detect viremia while serology re-
sults might be inconclusive in this cohort of patients. Phenomenon
of chromosomal integration of HHV6 (CI-HHV6) however
opened new era in interpretation of HHV6 PCR positivity. Since
CI-HHV6 could be inherited from parent, viral DNA can be de-
tected in every body cell. CI-HHV6 does not represent active
HHV6 infection and its prevalence in population is described be-
tween 1–2%. In such situation, misinterpretation of PCR positivity
may than lead to inadequate and potentially harmful therapy due to
risks of unsubstantiated toxicity and side effects.
In situation of allogeneic HSCT, it is possible to observe increase
in HHV6 positivity caused by the engraftment of the cells from CI-
HHV6 positive donor, or decrease in detected HHV6 DNA after
HSCT in CI-HHV6 positive recipient transplanted with the donor
without CI-HHV6.
Between I/2002-X/2007 we have tested for HHV6 2057 samples
from 219 adult patients and 2553 samples from 107 children
patients after allogeneic HSCT. DNA was isolated from whole
blood and detection was performed using RQ-PCR. Results
were normalised to 10,000 human genomic equivalents accessed
by quantification of albumin gene. HHV6 was detected in 395
samples from 58 children and 144 samples from 40 adults. Within
three weeks after HSCT, we have detected more then 1,000 nor-
malised viral copies in 7 children and 4 adults. From these, we have
confirmed CI-HHV6 by documenting positivity in the pre-trans-
plant samples and the non-blood samples (hair follicles) in one
child and one adult. CI-HHV6 is highly probable also in two pa-
tients with variant B due to long lasting PCR positivity in post-
transplant surveillance and decrease shortly after HSCT (we are
working on CI-HHV6 confirmation). In none of the patients we
have observed post-transplant complications attributable to
HHV6. We excluded CI-HHV6 by the pre-transplant negativity
in the 7 remaining patients.Despite HHV6 is close related to human cytomegalovirus, in this
particular situation patients are endangered only by misinterpreta-
tion of highly positive viral DNA load and side effects of virostatics.
Therefore in case of high HHV6 DNA load we should be aware of
this phenomenon and we should try to excludeCI-HHV6 as soon as
possible.
Supported by FNM 00064203, MSMT0021620813.258
VORICONAZOLE IS EFFECTIVE PROPHYLAXIS FOR ASPERGILLUS INVA-
SIVE FUNGAL INFECTION (IFI) IN PATIENTS RECEIVING GLUCOCORTI-
COSTEROID THERAPY FOR GVHD AFTER ALLOGENEIC
TRANSPLANTATION
Gergis, U.1, Markey, K.2, Greene, J.1, Kharfan-Dabaja, M.1,
Wetzstein, G.2, Anasetti, C.1, Perkins, J.1. 1H. Lee Moffitt Cancer Cen-
ter & Research Institute, Tampa, FL; 2H. Lee Moffitt Cancer Center &
Research Institute, Tampa, FL.
Invasive fungal infections (IFI) are a significant cause of morbid-
ity and mortality after allogeneic hematopoietic cell transplant. Pa-
tients (pts) who develop graft versus host disease (GVHD) requiring
systemic glucocorticoids (GC) are especially vulnerable to IFI. The
findings of Ullmann et al. support the prophylactic use of posacona-
zole over either fluconazole (F) or itraconazole (I) in this pt popula-
tion. Efficacy of posaconazole, however, can be limited in pts with
gastrointestinal GVHDby the lack of an IV formulation. Voricona-
zole (V) offers advantages over posaconazole in the availability of an
IV formulation and improved oral bioavailability. Following FDA
approval, we began using V for prophylaxis in patients with
GVHD at the onset of GC therapy. Prior to that time either F or
I was given. To determine the antifungal efficacy of V compared
to F or I, we performed a retrospective review of 169 allogeneic
transplant pts who were placed on GC ($1 mg/kg/d of prednisone
or equivalent) for GVHD. Pts with IFI history before GVHDonset
were excluded. Study endpoints included proportion of pts with
proven or probable IFI by EORTC/MSG criteria during the first
100 days of GC therapy, time to IFI, and mortality due to IFI diag-
nosed within 100 days of the start of GC. Seventy-two pts received
either F (36 pts) or I (36 pts) (F/I) and 97 pts received V. V pts were
older, had higher risk disease, were more likely to have received
transplants of peripheral blood hematopoietic cells and from unre-
lated donors (all risk factors for GVHD and secondary IFI), but
were treated more recently and with reduced intensity regimens.
IFI developed in 7 F/I pts (9.7%) vs 2 V pts (2.1%) (p 5 0.03). F/
I pts included 5 cases (6.9%) of aspergillus (pneumonia [4] and
skin abcess [1]), and 2 cases of candidemia [C. krusei and C. glab-
rata]. V pts included 2 cases of candidemia (C. glabrata) and no as-
pergillus IFI. The proportion of pts developing aspergillus IFI was
significantly lower in the V pts (p 5 0.009). Five of the seven F/I
cases died from the IFI, one of pulmonary hemorrhage and one of
bacterial sepsis. Neither of the 2 V pts died as a result of their
IFI, one died from CNS hemorrhage and the other from GVHD.
Overall survival at 100 days after start of GC was 79% for F/I pts
and 85% for V pts (p 5 0.27). We conclude that voriconazole was
effective prophylaxis for aspergillus IFI in pts receiving GC therapy
for GVHD after allogeneic transplantation.259
TREATMENT OF DONOR GRAFT FAILURE WITH AUTOLOGOUS OR ALLO-
GENEIC STEM CELL BOOST OR A SECOND ALLOGENEIC TRANSPLANT
BASED ON CHIMERISM TESTING
Shimoni, A., Shem-Tov, N., Rand, A., Ribakovsky, E., Yerushalmi, R.,
Hardan, I., Nagler, A. Chaim Sheba Medical Center, Tel-Hashomer,
Israel.
Donor graft failure (GF) is a life-threatening complication of al-
logeneic stem cell transplantation (SCT). We performed this anal-
ysis to determine the rate and outcome of GF in the era of modern
SCT. We retrospectively reviewed data of 491 SCTs from HLA-
matched siblings (n 5 284), matched-unrelated (MUD, n 5 180)
